Selexipag is a non prostanoid IP prostacyclin receptor agonist used to treat pulmonary arterial hypertension. Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.
- Mechanism
- Curator reviewed
Selexipag is a selective prostacyclin (IP, also called PGI2) receptor agonist. The key features of pulmonary arterial hypertension include a decrease in prostacyclin and prostacyclin synthase (enzyme that helps produce prostacyclin) in the lung. Prostacyclin is a potent vasodilator with anti-proliferative, anti-inflammatory, and anti-thrombotic effects; therefore, there is strong rationale for treatment with IP receptor agonists. Selexipag is chemically distinct as it is not PGI2 or a PGI2 analogue and has high selectivity for the IP receptor. It is metabolized by carboxylesterase 1 to yield an active metabolite (ACT-333679) that is approximately 37 times more potent than selexipag. Both selexipag and its metabolite are selective for the IP receptor over other prostanoid receptors.
- Primary indication
- Selexipag is indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.Curator reviewed · 1 structured indication
- Formula / weight
- C26H32N4O4S · 496.63 g/mol (avg)
- First approval
- Canada, 2018 · United States, 2015 · European Union, 2016
- Code names
- ACT-293987 · JNJ-67896049 · NS-304
- Brand names
Resolves to
QXWZQTURMXZVHJ-UHFFFAOYSA-NSMILESCC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C1=CC=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Selexipag, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account